# Mendelian Disorders Testing Market

> Mendelian disorders testing market research report: by test type (carrier testing, diagnostic testing, new-born screening), by disorder (cystic fibrosis, sickle cell anemia), by end-user (hospitals, ascs, specialized clinics) – Global forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.01%
- **2024:** $ 0.43 Billion
- **2025:** $ 0.47 Billion
- **2035:** $ 1.23 Billion
- **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Agilent Technologies (US), F. Hoffmann-La Roche (CH), PerkinElmer (US), Myriad Genetics (US), Invitae (US), GeneDx (US), Sema4 (US)

**Report ID:** MRFR/LS/4053-HCR · **Pages:** 90 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/mendelian-disorders-testing-market-5500

---

## Market Summary

## **Global Mendelian Disorders Testing Market Overview**

Mendelian Disorders Testing Market Size was valued at USD 0.4 billion in 2023. The Mendelian Disorders Testing Market industry is projected to grow from USD 0.43 billion in 2024 to USD 0.96 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.54% during the forecast period (2024 - 2032). Genetic testing involves the use of laboratory methods to study the genes inherited from mother or father. These tests may be used to identify increased risks of health problems, to diagnose the mutations in the genes, to choose treatments, or to assess responses to treatment.

Mendelian disorders also known as monogenic diseases arise due to the modifications in a single gene occurring in all cells of the body. Currently, it is estimated that over 10,000 of human diseases are known to be monogenic. These disorders are responsible for a heavy loss of life. The global prevalence of monogenic diseases at birth is approximately 10 in every 1000 infants.

The Mendelian disorders are caused by a single mutated gene which can be present on single or both chromosomes. Both females and males are equally affected by this disorder. Sickle cell anemia, Cystic fibrosis,  Tay-Sachs disease, SCID, Gaucher's disease, Huntington's disease, neurofibromatosis, thalassemia, polycystic kidney disorder, and familial hypercholesterolemia are some of the common monogenic disorders. Nowadays, there are several tests performed to treat monogenic disorders such as diagnostic testing, carrier testing, predictive & pre-symptomatic testing, prenatal testing and new-born screening.

The carrier testing is a type of genetic testing that is used to determine a carrier person for monogenic disorders. Having said that, more and more genetic tests are being developed for a lot of other genetic disorders. [Oncology](../../../reports/oncology-information-systems-market-7080) segment has been the major focus area of the companies developing these tests as the large pool of population is affected by this fatal disease. The continuous rise in the prevalence of the genetic disorders has boosted the growth of the genetic testing market.

**Intended Audience**

## **Mendelian Disorders Testing Market Segmentation**

The Mendelian disorders testing market is segmented on the basis of test type, disorder type, and end-user.

### **Mendelian Disorders Testing Type Insights**

On the basis of the test type, the Mendelian disorders testing market is segmented into carrier testing, diagnostic testing, new-born screening, predictive & pre-symptomatic testing, prenatal testing, and others

### **Mendelian Disorders Testing Disorder Type Insights**

On the basis of the disorder type, the mendelian disorders testing market is segmented into cystic fibrosis, sickle cell anemia, severe combined immunodeficiency (SCID), Tay-Sachs disorder, polycystic kidney disorder, Gaucher's disease, Huntington's disease, neurofibromatosis, thalassemia, familial hypercholesterolemia, and others

### **Mendelian Disorders Testing End-User Insights**

On the basis of the end user, the mendelian disorders testing market is segmented into hospitals, ambulatory surgical centers (ASCs), and specialized clinics.

### **Mendelian Disorders Testing Regional Insights**

The Mendelian disorders testing market is segmented as the Americas, Europe, Asia Pacific and the Middle East and Africa.

The Americas is projected to hold the largest share of the mendelian disorders testing market. The unique opportunity drives the Mendelian disorders testing the market, and the focused issues stress on the need for more research on monogenic disorder tests.  In the United States, sickle cell anemia affects around 72,000 people, the majority of this population have their ancestors from Africa. All the factors above are anticipated to boost the market growth in the U.S. and ensure its dominance over the forecast period.

Europe is expected to capture the second lead in this market in the coming five years owing to substantial technological advancements. About 6,000 people are affected with hemophilia in the UK. Moreover, about 5400 people in the U.K with hemophilia A and about 1100 with[hemophilia](../../../reports/hemophilia-treatment-market-5688) B.

The market in the Asia Pacific is expected to witness the fastest growth rate due to increasing prevalence of monogenic disorders throughout the globe, which will boost the growth of the monogenetic disorders testing market.

The Middle East and Africa are also expected to show healthy growth in the coming five years.

## **Mendelian Disorders Testing Market Key Players**

The existing players are strengthening their foothold in the industry by introducing technologically advanced products. Regulatory bodies such as the US FDA and the European CE mark, although stringent, are approving equipment that fulfills all clinical data requirement and other safety criteria.

## Market Drivers

### Rising Prevalence of Mendelian Disorders

The increasing prevalence of Mendelian disorders is a critical factor driving the Mendelian Disorders Testing Market. Conditions such as [cystic fibrosis](https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825), [sickle cell disease](https://www.marketresearchfuture.com/reports/sickle-cell-disease-market-24662), and Huntington's disease are becoming more recognized, leading to a greater need for effective diagnostic solutions. Epidemiological studies indicate that approximately 1 in 200 individuals are affected by a Mendelian disorder, underscoring the urgency for comprehensive testing options. As awareness of these conditions grows, so does the demand for genetic testing services that can provide accurate diagnoses and inform treatment decisions. This rising prevalence is likely to stimulate market growth, as healthcare systems strive to address the needs of affected populations.

### Regulatory Developments and Standardization

The Mendelian Disorders Testing Market is influenced by evolving regulatory frameworks aimed at ensuring the safety and efficacy of genetic testing. Regulatory bodies are increasingly focusing on standardizing testing procedures and validating the accuracy of results. This is particularly crucial as the market expands, with numerous new testing services entering the landscape. Enhanced regulations not only foster consumer trust but also encourage innovation among testing providers. As a result, companies are investing in compliance and quality assurance measures, which may lead to improved testing outcomes. The establishment of clear guidelines is anticipated to facilitate market growth, as stakeholders navigate the complexities of genetic testing.

### Technological Advancements in Genetic Testing

The Mendelian Disorders Testing Market is experiencing a transformative phase due to rapid technological advancements. Innovations such as next-generation sequencing (NGS) and CRISPR [gene editing](https://www.marketresearchfuture.com/reports/gene-editing-market-707) are revolutionizing the landscape of genetic testing. These technologies enable more accurate and efficient identification of genetic mutations associated with Mendelian disorders. For instance, NGS allows for the simultaneous analysis of multiple genes, significantly reducing the time and cost associated with traditional testing methods. As a result, the market is projected to grow at a compound annual growth rate (CAGR) of approximately 12% over the next five years. This growth is driven by the increasing adoption of these advanced technologies in clinical settings, enhancing diagnostic capabilities and patient outcomes.

### Increased Awareness and Demand for Genetic Testing

The rising awareness regarding genetic disorders and the benefits of early diagnosis is propelling the Mendelian Disorders Testing Market forward. Educational initiatives and advocacy from healthcare professionals have led to a heightened understanding of genetic testing among the public. This awareness is reflected in the increasing demand for testing services, as individuals seek proactive measures for health management. According to recent surveys, nearly 60% of individuals express interest in genetic testing for hereditary conditions. This trend is likely to continue, as more people recognize the importance of genetic information in making informed healthcare decisions. Consequently, the market is expected to expand, driven by this growing consumer demand.

### Integration of Genetic Testing in Clinical Practice

The integration of Mendelian disorders testing into routine clinical practice is a significant driver for the Mendelian Disorders Testing Market. Healthcare providers are increasingly recognizing the value of genetic testing in diagnosing and managing hereditary conditions. This integration is supported by clinical guidelines recommending genetic testing for specific patient populations, thereby enhancing the overall quality of care. As healthcare systems adopt personalized medicine approaches, the demand for genetic testing is expected to rise. Furthermore, the collaboration between genetic testing laboratories and healthcare providers is likely to streamline the testing process, making it more accessible to patients. This trend is indicative of a broader shift towards precision medicine, which is anticipated to bolster market growth.

## Future Outlook

The Mendelian Disorders Testing Market is projected to grow at a 10.01% CAGR from 2025 to 2035, driven by advancements in genetic research, increasing awareness, and technological innovations.

**New opportunities:**

- Development of AI-driven genetic analysis platforms
- Expansion of telehealth services for remote testing
- Partnerships with healthcare providers for integrated testing solutions

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Type: Carrier Testing (Largest) vs. Diagnostic Testing (Fastest-Growing)

In the Mendelian Disorders Testing Market, the carrier testing segment holds the largest share, primarily driven by increasing awareness and demand for genetic insights among prospective parents. This testing type is pivotal in identifying carriers of genetic mutations, which helps in making informed reproductive choices. On the other hand, the diagnostic testing segment is observing the fastest growth due to advancements in technology and a rise in genetic disorder diagnoses. With a growing emphasis on early detection, this segment is gaining significant traction.

Carrier Testing (Dominant) vs. Diagnostic Testing (Emerging)

Carrier testing is currently the dominant force in the Mendelian Disorders Testing Market, characterized by its pivotal role in reproductive decision-making. It provides comprehensive insights into genetic carrier status, ensuring that individuals and families can make informed choices regarding family planning. This segment benefits from increased public awareness and evolving societal norms surrounding genetic information. Conversely, the diagnostic testing segment is emerging rapidly, fueled by advancements in sequencing technologies and a heightened focus on early detection of genetic disorders. This segment appeals to healthcare providers and patients alike, driven by a need for accurate diagnosis and management of genetic conditions.

### By Disorder Type: Cystic Fibrosis (Largest) vs. Sickle Cell Anemia (Fastest-Growing)

In the Mendelian Disorders Testing Market, the distribution of market share among different disorder types illustrates a clear hierarchy, with Cystic Fibrosis emerging as the dominant disorder type. This is followed closely by Sickle Cell Anemia, which is gaining traction, especially in regions with high prevalence. Other notable disorder types such as Tay-Sachs, Gaucher's Disease, and Huntington's Disease contribute to the market, but their shares remain comparatively smaller. Overall, the diversity of disorders reflects varying healthcare needs and genetic testing demands across regions.

Growth trends in the Mendelian Disorders Testing Market indicate a surge in demand for Sickle Cell Anemia testing, primarily driven by increased awareness and screening programs. Advances in genetic testing technologies and growing understanding of these disorders also play a critical role. Health initiatives promoting early diagnosis significantly enhance the accessibility and acceptance of testing, thereby propelling the market forward. Cystic Fibrosis remains a steadfast segment due to its established testing protocols and patient care frameworks, continuing to attract investments and research.

Cystic Fibrosis (Dominant) vs. Sickle Cell Anemia (Emerging)

Cystic Fibrosis is recognized as a dominant segment in the Mendelian Disorders Testing Market, primarily due to well-established screening and diagnostic guidelines that facilitate early identification and intervention. This disorder has fostered significant advancements in treatment protocols, thus reinforcing the need for regular testing. In contrast, Sickle Cell Anemia is emerging rapidly, driven by an increase in genetic awareness and state-sponsored screening initiatives, particularly in high-prevalence regions. As healthcare systems become increasingly focused on personalized medicine, both disorders illustrate the dynamic landscape of genetic testing, with Cystic Fibrosis solidifying its foothold and Sickle Cell Anemia positioned for accelerated growth.

### By End User: Hospitals (Largest) vs. Specialized Clinics (Fastest-Growing)

The Mendelian Disorders Testing Market showcases a diverse landscape of end users, predominantly led by hospitals, which account for a significant share of the market. Ambulatory surgical centers (ASCs) also contribute meaningfully, though they hold a smaller fraction compared to hospitals. Specialized clinics have emerged as vital players, rapidly capturing attention due to their focused offerings and specialized care.

In recent years, the growth trend within this segment has been propelled by several factors. Hospitals continue to prioritize comprehensive screening and diagnostic capabilities, while increasing patient awareness drives demand at specialized clinics. Furthermore, technological advancements in genetic testing and a push for personalized medicine are encouraging ASCs to adopt these testing methods, potentially altering the competitive dynamics of the market.

Hospitals (Dominant) vs. Specialized Clinics (Emerging)

Hospitals remain the dominant force in the Mendelian Disorders Testing Market due to their extensive resources, established patient infrastructure, and comprehensive care capabilities. They typically have access to advanced diagnostic tools and a multidisciplinary approach to genetic testing, which positions them as first-line facilities for testing and management of Mendelian disorders. In contrast, specialized clinics are emerging quickly, catering to patients who seek targeted [genetic counseling](https://www.marketresearchfuture.com/reports/genetic-counseling-market-19215) and testing services tailored to specific conditions. This shift towards specialization is driven by patient demand for customized care, leading specialists in genetic disorders to establish outpatient models that enhance accessibility and focus on individualized treatment plans.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America is the largest market for Mendelian disorders testing, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing awareness of genetic disorders, and supportive regulatory frameworks. The demand for personalized medicine and genetic testing is on the rise, further propelled by government initiatives promoting research and development in genomics.

The United States is the leading country in this market, with significant contributions from key players such as Illumina, Thermo Fisher Scientific, and Myriad Genetics. The competitive landscape is characterized by continuous innovation and strategic partnerships among these companies. Canada also plays a vital role, with increasing investments in genetic research and testing services, enhancing the overall market dynamics.

### Europe : Regulatory Support and Growth

Europe is the second-largest market for Mendelian disorders testing, holding around 30% of the global market share. The region benefits from robust healthcare systems and increasing government support for genetic research. Regulatory bodies are actively promoting the integration of genetic testing into clinical practice, which is driving demand. The European Union's initiatives to standardize genetic testing protocols are also contributing to market growth.

Leading countries in this region include Germany, France, and the United Kingdom, where significant investments in healthcare technology are being made. The competitive landscape features major players like F. Hoffmann-La Roche and Agilent Technologies, which are focusing on innovative solutions to enhance testing accuracy. The presence of numerous startups in the genetic testing space is also fostering a dynamic market environment.

### Asia-Pacific : Emerging Market Potential

Asia-Pacific is witnessing rapid growth in the Mendelian disorders testing market, accounting for approximately 20% of the global share. The region's growth is fueled by increasing healthcare expenditure, rising awareness of genetic disorders, and advancements in technology. Countries like China and India are leading this growth, driven by government initiatives to enhance healthcare access and promote genetic research.

China is the largest market in the region, with significant investments in biotechnology and genetic testing infrastructure. India is also emerging as a key player, with a growing number of diagnostic laboratories offering genetic testing services. The competitive landscape is evolving, with both established companies and new entrants focusing on innovative testing solutions to meet the rising demand.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the Mendelian disorders testing market, holding about 5% of the global share. The growth is driven by increasing awareness of genetic disorders and the need for advanced healthcare solutions. Governments are beginning to recognize the importance of genetic testing, leading to initiatives aimed at improving healthcare infrastructure and access to genetic services.

Countries like South Africa and the UAE are at the forefront of this growth, with investments in healthcare technology and genetic research. The competitive landscape is still developing, with a mix of local and international players entering the market. The presence of key players is expected to increase as demand for genetic testing rises, creating new opportunities for growth in the region.

## Competitive Benchmarking

The Mendelian Disorders Testing Market is characterized by a dynamic competitive landscape, driven by advancements in genetic testing technologies and an increasing prevalence of genetic disorders. Key players such as Illumina (US), Thermo Fisher Scientific (US), and F. Hoffmann-La Roche (CH) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Illumina (US) focuses on next-generation sequencing technologies, which are pivotal in providing comprehensive genetic insights, while Thermo Fisher Scientific (US) emphasizes a broad portfolio of diagnostic solutions that cater to various genetic testing needs. F. Hoffmann-La Roche (CH) is strategically positioned through its robust research and development initiatives, aiming to integrate precision medicine into routine clinical practice. Collectively, these strategies foster a competitive environment that prioritizes technological advancement and collaborative efforts.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the Mendelian Disorders Testing Market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive innovation, thereby shaping the overall market dynamics.

In August 2025, Illumina (US) announced a strategic partnership with a leading healthcare provider to expand access to its genetic testing services. This collaboration is expected to enhance patient access to advanced genetic diagnostics, thereby potentially increasing the adoption of Mendelian disorder testing. The strategic importance of this partnership lies in its ability to bridge the gap between cutting-edge technology and clinical application, ultimately improving patient outcomes.

In September 2025, Thermo Fisher Scientific (US) launched a new suite of genetic testing solutions aimed at streamlining the diagnostic process for Mendelian disorders. This launch is significant as it reflects the company's commitment to innovation and its response to the growing demand for rapid and accurate genetic testing. By enhancing its product offerings, Thermo Fisher Scientific (US) positions itself as a leader in the market, catering to the evolving needs of healthcare providers and patients alike.

In July 2025, F. Hoffmann-La Roche (CH) expanded its portfolio by acquiring a biotechnology firm specializing in gene therapy. This acquisition is indicative of Roche's strategy to diversify its offerings and integrate advanced therapeutic solutions with diagnostic capabilities. The strategic importance of this move lies in its potential to create a comprehensive approach to managing Mendelian disorders, combining diagnostics with innovative treatment options.

As of October 2025, current competitive trends in the Mendelian Disorders Testing Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their technological capabilities and market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains. This shift underscores the importance of not only meeting market demands but also anticipating future trends in genetic testing.

## Report Scope

| MARKET SIZE 2024 | 0.43(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.473(USD Billion) |
| MARKET SIZE 2035 | 1.228(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.01% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Agilent Technologies (US), F. Hoffmann-La Roche (CH), PerkinElmer (US), Myriad Genetics (US), Invitae (US), GeneDx (US), Sema4 (US) |
| Segments Covered | test type, disorder, end-user |
| Key Market Opportunities | Advancements in genomic technologies enhance accuracy and accessibility in the Mendelian Disorders Testing Market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the Mendelian Disorders Testing market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Mendelian Disorders Testing Market?**
A: The Mendelian Disorders Testing Market was valued at 0.43 USD Billion in 2024.

**Q: What is the projected market size for the Mendelian Disorders Testing Market by 2035?**
A: The market is projected to reach 1.228 USD Billion by 2035.

**Q: What is the expected CAGR for the Mendelian Disorders Testing Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 10.01%.

**Q: Which companies are considered key players in the Mendelian Disorders Testing Market?**
A: Key players include Illumina, Thermo Fisher Scientific, Agilent Technologies, and F. Hoffmann-La Roche.

**Q: What are the main segments of the Mendelian Disorders Testing Market?**
A: The main segments include carrier testing, diagnostic testing, newborn screening, and prenatal testing.

**Q: How did the carrier testing segment perform in 2024?**
A: In 2024, the carrier testing segment was valued at approximately 0.086 USD Billion.

**Q: What is the projected value of the diagnostic testing segment by 2035?**
A: The diagnostic testing segment is expected to reach around 0.372 USD Billion by 2035.

**Q: Which disorder types are most prevalent in the Mendelian Disorders Testing Market?**
A: Cystic fibrosis and sickle cell anemia are among the most prevalent disorder types, with values of 0.05 and 0.07 USD Billion in 2024, respectively.

**Q: What is the expected growth for specialized clinics in the Mendelian Disorders Testing Market?**
A: The specialized clinics segment is projected to grow to approximately 0.368 USD Billion by 2035.

**Q: How does the market's growth potential compare across different end users?**
A: Hospitals are expected to dominate the market, with a valuation of 0.615 USD Billion projected for 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/mendelian-disorders-testing-market-5500*